Wound Infections Department, Bacterial Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA.
F. Edward Hébert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA.
Viruses. 2022 Mar 29;14(4):708. doi: 10.3390/v14040708.
is an emerging opportunistic Gram-negative pathogen with reports of increasing antibiotic resistance. Pan-drug resistant (PDR) infections are a growing concern, demonstrating a need for the development of alternative treatment options which is fueling a renewed interest in bacteriophage (phage) therapy. Here, we identify and characterize phage vB_PreP_EPr2 (EPr2) with lytic activity against PDR MRSN 845308, a clinical isolate that carries multiple antibiotic resistance genes. EPr2 was isolated from an environmental water sample and belongs to the family , subfamily and genus , with a genome size of 41,261 base pairs. Additional phenotypic characterization showed an optimal MOI of 1 and a burst size of 12.3 ± 3.4 PFU per bacterium. EPr2 was determined to have a narrow host range against a panel of clinical strains. Despite this fact, EPr2 is a promising lytic phage with potential for use as an alternative therapeutic for treatment of PDR infections.
是一种新兴的机会性病原体，具有抗生素耐药性不断增加的报道。泛耐药（PDR）感染是一个日益令人关注的问题，这表明需要开发替代治疗方案，这也促使人们重新关注噬菌体（噬菌体）治疗。在这里，我们鉴定并表征了噬菌体 vB_PreP_EPr2（EPr2），它对 PDR MRSN 845308 具有溶菌活性，MRSN 845308 是一种临床分离株，携带多种抗生素耐药基因。EPr2 是从环境水样中分离出来的，属于科、亚科和属，基因组大小为 41261 个碱基对。进一步的表型特征表明最佳 MOI 为 1，每个细菌的爆发大小为 12.3±3.4PFU。EPr2 对一组临床菌株的宿主范围较窄。尽管如此，EPr2 是一种有前途的溶菌噬菌体，具有作为治疗 PDR 感染的替代治疗方法的潜力。
